Adverse event totals15

The totals the trial posted for each group.

1 to 15 of 15

Total	Group	Affected	At risk
Total, all-cause mortality	Stage 1- Placebo	0	78
Total, all-cause mortality	Stage 1- Venglustat 8 mg	0	78
Total, all-cause mortality	Stage 1- Venglustat 15 mg	0	80
Total, all-cause mortality	Stage 2- Placebo	0	122
Total, all-cause mortality	Stage 2- Venglustat 15 mg	0	119
Total, other adverse events	Stage 1- Placebo	42	78
Total, other adverse events	Stage 1- Venglustat 8 mg	46	78
Total, other adverse events	Stage 1- Venglustat 15 mg	48	80
Total, other adverse events	Stage 2- Placebo	32	122
Total, other adverse events	Stage 2- Venglustat 15 mg	48	119
Total, serious adverse events	Stage 1- Placebo	8	78
Total, serious adverse events	Stage 1- Venglustat 8 mg	15	78
Total, serious adverse events	Stage 1- Venglustat 15 mg	19	80
Total, serious adverse events	Stage 2- Placebo	6	122
Total, serious adverse events	Stage 2- Venglustat 15 mg	7	119

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03523728/event-totals